Immunologic Interplay Between HIV/AIDS and COVID-19: Adding Fuel to the Flames?
Matteo AugelloValeria BonoRoberta RovitoCamilla TincatiGiulia Carla MarchettiPublished in: Current HIV/AIDS reports (2023)
Overall, current literature shows that COVID-19 severity and outcomes may be worse and immune responses to infection or vaccination lower in PLWH with poor CD4 + T-cell counts and/or uncontrolled HIV viremia. Data regarding the risk of post-acute sequelae of SARS-CoV-2 infection (PASC) among PLWH are extremely scarce, yet they seem to suggest a higher incidence of such condition. Scarce immunovirological control appears to be the major driver of weak immune responses to SARS-CoV-2 infection/vaccination and worse COVID-19 outcomes in PLWH. Therefore, such individuals should be prioritized for vaccination and should receive additional vaccine doses. Furthermore, given the potentially higher risk of developing long-term sequelae, PLWH who experienced COVID-19 should be ensured a more careful and prolonged follow-up.
Keyphrases
- coronavirus disease
- sars cov
- hiv aids
- immune response
- respiratory syndrome coronavirus
- antiretroviral therapy
- hiv infected
- risk factors
- human immunodeficiency virus
- systematic review
- hiv positive
- dendritic cells
- electronic health record
- adipose tissue
- machine learning
- metabolic syndrome
- big data
- hepatitis b virus
- acute respiratory distress syndrome
- men who have sex with men
- weight loss
- data analysis